EMA Authorised: M-M-RVaxPro (measles virus Enders’ Edmonston strain (live, attenuated);mumps virus Jeryl Lynn (level B) strain (live, attenuated);rubella virus Wistar RA 27/3 strain (live, attenuated)) — Merck Sharp & Dohme B.V.

View source ↗

Summary

The EMA authorised Merck's M-M-RVaxPro, a live attenuated measles‑mumps‑rubella vaccine, for immunization against measles, mumps and rubella.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Measles
• Mumps
• Rubella

Drugs mentioned

• M-M-RVaxPro

Snippet

Status: Authorised. Therapeutic area: Rubella;Mumps;Immunization;Measles. MAH: Merck Sharp & Dohme B.V.. Decision date: 30/10/2025